Patients with KRAS wild-type tumours were randomised 2:1 to afatinib ( 40 mg/day , increasing to 50 mg/day if minimal toxicity ) or cetuximab weekly ( 400 mg/m2 loading dose , then 250 mg/m2/week ) according to number of previous chemotherapy lines .